MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2026.10.012

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2026

A Phase 1 Trial Investigating the Addition of Papaverine to Stereotactic Body Radiotherapy (SBRT) for Hypoxic Radiosensitization of Lung Tumors.

Brownstein Jeremy, Williams Terence, Xu-Welliver Meng, Sebastian Nikhil, Ma Sung Jun, Haglund Karl, Sim Austin, Benej Martin, Papandreou Ioanna, Qing Kun, Wei Lai, Graves Edward, Denko Nicholas

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Tumor hypoxia has been recognized as a barrier to effective radiotherapy. Preclinical work identified the FDA approved smooth muscle relaxant papaverine (PPV) as having an "off target" activity as a mitochondrial inhibitor that reduces hypoxia and radiosensitizes model tumors.

METHODS

We conducted an IRB-approved phase 1 clinical trial to evaluate safety and feasibility of adding PPV to stereotactic body radiation therapy (SBRT) for tumors of the lung. Eligible patients with early-stage non-small cell lung cancer (NSCLC) or limited lung metastases who were candidates for SBRT (50 Gy in 4 or 5 fractions) were enrolled. Based on a Bayesian Optimal Interval (BOIN) design, patients were allocated to receive PPV 30-90 minutes prior to each SBRT fraction at 3 dose levels (DL): 0.5 mg/kg (DL-1), 1 mg/kg (DL1), or 2mg/kg (DL2).

RESULTS

Nineteen patients enrolled and 18 completed study treatment and were evaluable, with a median follow up of 33.4 months. Among 18 evaluable patients, 7 had early-stage NSCLC, 2 had metastatic NSCLC, and 8 had lung metastases from other histologies. The maximum tolerated dose (MTD) was determined to be DL2, which had a dose limiting toxicity (DLT) rate posterior estimate of 0.17 (95% CI 0.01 to 0.53). The 2-year controls rates for local, regional and distant control were 100%, 94% and 82%, respectively.

CONCLUSIONS

We demonstrate the feasibility and safety of PPV as a hypoxic radiosensitizer for SBRT. The MTD for this patient population is at least 2 mg/kg of PPV. Encouraging clinical results indicate that further investigation of PPV's utility as a tumor-selective radiosensitizer is warranted.

Для цитирования: Brownstein Jeremy, Williams Terence, Xu-Welliver Meng, Sebastian Nikhil, Ma Sung Jun, Haglund Karl, Sim Austin, Benej Martin, Papandreou Ioanna, Qing Kun, Wei Lai, Graves Edward, Denko Nicholas. A Phase 1 Trial Investigating the Addition of Papaverine to Stereotactic Body Radiotherapy (SBRT) for Hypoxic Radiosensitization of Lung Tumors.. International journal of radiation oncology, biology, physics. 2026. DOI: 10.1016/j.ijrobp.2026.10.012.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.